Other Vaccines - Ireland

Ireland

Highlights

The projected revenue in the Other Vaccines market in Ireland is expected to reach US$108.60m in 2024.
This revenue is anticipated to demonstrate an annual growth rate (CAGR 2024-2029) of 9.97%, leading to a market volume of US$174.70m by 2029.
When compared to other countries worldwide, United States is forecasted to generate the highest revenue of US$24.73bn in 2024.
Ireland is witnessing a growing demand for other vaccines, driven by the government's focus on public health and increasing awareness among its population.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Other Vaccines market in Ireland has been steadily growing over the past few years.

Customer preferences: Irish consumers have shown a growing interest in preventative healthcare, including vaccinations. This trend has been supported by the Irish government's efforts to increase vaccination rates in the country. Additionally, the COVID-19 pandemic has raised awareness about the importance of vaccinations, which has likely contributed to the growth of the Other Vaccines market.

Trends in the market: The Other Vaccines market in Ireland has seen growth in several areas, including travel vaccines, HPV vaccines, and meningitis vaccines. The growth in travel vaccines can be attributed to the increasing number of Irish citizens traveling abroad. The HPV vaccine has also seen increased demand due to the Irish government's decision to offer the vaccine to boys in addition to girls. Finally, the meningitis vaccine has seen growth due to several outbreaks of the disease in recent years.

Local special circumstances: One unique aspect of the Irish market is the country's vaccination schedule. Ireland has a more comprehensive vaccination schedule than many other countries, which includes several vaccines that are not included in other countries' schedules. This has likely contributed to the growth of the Other Vaccines market in Ireland.

Underlying macroeconomic factors: The Irish economy has been growing steadily in recent years, which has likely contributed to the growth of the Other Vaccines market. Additionally, the Irish healthcare system is relatively well-funded and provides universal healthcare to all citizens. This has likely made it easier for Irish consumers to access vaccines and contributed to the growth of the market.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.